On the stock market since 2024, it operates in the world of health and science. It has 118 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 219% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 1.8× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 10% of them.
Analysts' average target sits 1,079% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Business Quality: Profit power and business quality trail similar companies in the sector.
An investor who bought at the very peak is down 90% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 14% a year on average.
Sales run at $25.2M a year. A small number, but proof the product has real buyers.
There is $160.8M in the vault; even if every debt were paid off, $120.1M would remain.
A loss of $87.9M against $25.2M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts about 1.8 years. After that, the company needs to find new money.
On our five-subject report card, MGX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: MGX is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (10/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.